November 20, 2019
  • November 20, 2019
Breaking News
  • Home
  • Technology
  • Fiat Chrysler Automobiles N.V. (NYSE:FCAU) plans to eliminate third shift at Windsor, Ont., minivan plant

Fiat Chrysler Automobiles N.V. (NYSE:FCAU) plans to eliminate third shift at Windsor, Ont., minivan plant

By on June 26, 2019 0

Fiat Chrysler Automobiles N.V. (NYSE:FCAU) plans to eliminate the third shift at its Windsor, Ont., minivan plant on Oct. 21, three weeks later than originally planned, due to a fleet order. FCA pushed the elimination date back from Sept. 30 “to accommodate a large order,” spokeswoman LouAnn Gosselin said in a statement. “After that date, the plant will return to a traditional two-shift operation.”

Fiat Chrysler Automobiles N.V. (NYSE:FCAU) shares slumped -1.57% to finally closed at $13.77 in last active session. 

FCAU’s distance from 20 day simple moving average is 2.56% and distance from 50-Day simple moving average is 0.94%.

Analyst’s mean target price for FCAU is $21.11 while analysts mean recommendation is 2.00. Stock value has moved between $12.63 – 18.36 in last one year. Analyst’s mean target price for FCAU is $21.11 while analysts mean recommendation is 2.00. 

Fiat Chrysler Automobiles N.V. (NYSE:FCAU) yearly performance is -20.38%. Annual EPS Growth of past 5 years is 46.69%. The current share price indicates that stock is -25.31% away from its one year high and is moving 9.46% ahead of its 52-week low. 



On 25 June 2018, Mylan N.V. (NASDAQ:MYL) shares climbs 3.84% and ultimately finalized to $18.65 in last traded day. Stock has got OUTPERFORM rating from 8 of Thomson Reuters analysts, 6 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for MYL is $30.56 while analysts mean recommendation is 2.10. 



At the movement Halozyme Therapeutics, Inc. (NASDAQ:HALO) is under coverage by number of analysts. Buy rating has been given by 2 analysts to the company stock whereas 1 given UNDERPERFORM rating to stock and 3 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is -0.14 and their mean rating for the stock is 2.60 on scale of 1-5. Analysts mean target price for Halozyme Therapeutics, Inc. (NASDAQ:HALO) is $20.22 while their mean recommendation is 2.60 (1=Buy, 5=sell). 

If we look at stock performance in last active day trading, we see that stock has moved climbs 1.06% to end the day at $16.28. The current share price indicate that stock is -13.63% away from its one year high and is moving 22.96% ahead of its 52-week low. 

Leave a comment